PubMed Health⌕ Search

Biomedical subjects

F Jané

Publications and source records attributed to F Jané.

62 records · Page 4Linked to original sources
PubMed1982

Possible mechanisms involved in the hyperthermic effect caused by reserpine after pretreatment with amphetamine or tranylcypromine in conscious rat.

Reserpine injected intravenously induced a hyperthermic response in rats pretreated one hour before with amphetamine or tranylcypromine. Pretreatment of rats with alpha-methyl-p-tyrosine (alpha-MT) before the interaction of tranylcypromine-reserpine or amphetamine-reserpine, significantly blocked the potentiation of the increase in temperature that was seen after reserpine. Pretreatment with p-chloro-phenyl-alanine (PCPA) partially abolished the potentiation of the increase in temperature that was seen after reserpine. The dopamine receptor antagonists prevented the hyperthermia induced by the interaction of tranylcypromine-reserpine. However, they only partially inhibited the rise of body temperature induced by reserpine in rats pretreated with amphetamine. Methysergide, a serotoninergic receptor blocker, only reduced the hyperthermic effect in both instances. In conclusion, in the rat potentiation of the increase in temperature induced by tranylcypromine before reserpine would appear to involve a main dopaminergic component and a lesser but significant noradrenergic and serotoninergic component. However, in hyperthermia induced by the combination of amphetamine plus reserpine it is unknown which of these amines plays a predominant role in the development of hyperthermia.

Amphetamine↗
PubMedDate not supplied

Pharmacokinetics of triflusal and its main metabolite HTB in healthy subjects following a single oral dose.

The pharmacokinetic profile of triflusal (2-acetoxy-4-trifluoromethyl benzoic acid) and its main metabolite HTB (2-hydroxy-4-trifluoromethyl benzoic acid) has been studied in 8 healthy subjects (4 males and 4 females), after a single oral dose of 900 mg of triflusal. Plasma concentrations were determined by a sensitive HPLC method. Sampling was performed up to 120 h post medication. Triflusal displays a Cmax of 11.6 +/- 1.7 micrograms/ml and a tmax of 0.88 +/- 0.26 h. The elimination half-life (t1/2) was 0.55 h with a clearance (Cl/F) of 45.5 +/- 11.0 l/h. HTB kinetic parameters were: tmax 4.96 +/- 1.37 h and Cmax 92.7 +/- 17.1 micrograms/ml, with an elimination t1/2 of 34.3 +/- 5.3 and a clearance of 0.18 +/- 0.04 l/h. The results obtained in this study show a rapid absorption of triflusal and an immediate biotransformation into HTB. The long lasting platelet anti-aggregatory effect of triflusal in spite of its short t1/2, could be explained by the irreversible inhibition of platelet cyclo-oxygenase and the sustained levels of HTB, which also possess anti-aggregant properties.

Administration, Oral↗
PubMedDate not supplied

[Pharmacological treatment of Alzheimer's disease: present situation and perspectives].

Alzheimer's disease (AD) is the commonest cause of dementia. Although its ethology is unknown, there is increasing evidence in support of the view that an abnormal degradation of the amyloid precursor protein (APP), perhaps influenced by a number of genetic, tisular or environmental factors, may be the primary cause of the many biochemical and morphological disorders that exist in the associative areas of the brain of these patients. Histopathologically it can be shown by the presence of extracellular senile plaques, intraneuronal fibrilar tangles and neuronal loss. There is no specific pharmacological treatment at present to prevent the disease or its development, in spite of the numerous and diverse drugs studied. Many of these studies are methodologically inadequate. The attempt of activating the cholinergic system has deserved special attention. A reversible inhibitor of acetylcholinesterase, tacrine, has been approved in the United States and other countries for the symptomatic treatment of mild to moderate AD, but its use still arises many questions. Different drug and non drug related interventions may be of great value in the care of these patients, and may influence the specific pharmacological treatments. The complexity and heterogeneity of AD and the multiple factors which may take part in its evolution make it necessary to place special attention on the methodological aspects of the clinical trials with new drugs for the treatment of this disease.

Alzheimer Disease↗